Genomes and Genes
Summary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
Publications205 found, 100 shown here
- Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteersInese Cebere
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
Vaccine 24:417-25. 2006..HIVA DNA and MVA.HIVA vaccines either alone or in a prime-boost regime to healthy HIV-1/2-negative adults indicated that the vaccines were safe and warranted further testing of this approach in larger phase I/II studies...
- Requirement for CD4 T cell help in generating functional CD8 T cell memoryDevon J Shedlock
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Science 300:337-9. 2003..These results demonstrate a previously undescribed role for CD4 help in the development of functional CD8 memory...
- Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infectionYasushi Miyahira
Atopy Research Center, Department of Parasitology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
Infect Immun 73:7356-65. 2005..cruzi. These results indicated, for the first time, that the induction of immune responses against a single CD8+-T-cell epitope derived from an intrinsic T. cruzi antigen was sufficient to control lethal T. cruzi infection...
- The success and failure of BCG - implications for a novel tuberculosis vaccinePeter Andersen
Statens Serum Institute, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark
Nat Rev Microbiol 3:656-62. 2005..Here, we discuss the potential mechanisms behind the variation of BCG efficacy and their implications for an improved TB vaccination strategy...
- Jump-starting the immune system: prime-boosting comes of ageDavid L Woodland
Trudeau Institute, 154 Algonquin Ave, Saranac Lake, NY 12983, USA
Trends Immunol 25:98-104. 2004..This Review discusses the impact of these recent developments on the future of prime-boost vaccine strategies...
- Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth
Division of Infectious Disease, Department of Internal Medicine, University of California at Davis, Sacramento, CA 95618, USA
J Infect Dis 201:132-41. 2010..We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines...
- Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune responseI Ramos
Centro de Investigaciones Biologicas, Spanish Research Council, Ramiro de Maeztu 9, 28040 Madrid, Spain
Vaccine 26:333-44. 2008....
- A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challengeS J Dunachie
University of Oxford, Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Rd, Headington, Oxford OX3 7LJ, United Kingdom
Infect Immun 74:5933-42. 2006..033). No protection was observed in the DDM-CS group. Prime-boost vaccination with DNA and MVA encoding ME-TRAP but not CS resulted in partial protection against P. falciparum sporozoite challenge in the present study...
- Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virusT M Herremans
Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment RIVM, Bilthoven, The Netherlands
J Immunol 162:5011-8. 1999..It is concluded that IPV vaccination alone is insufficient to induce a mucosal IgA response against poliovirus. In mucosally (OPV-) primed individuals, however, booster vaccination with IPV leads to a strong mucosal IgA response...
- Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosisJun Wang
Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
J Immunol 173:6357-65. 2004..Our study also lends strong evidence that respiratory mucosal vaccination is critically advantageous over systemic routes of vaccination against TB...
- Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther
Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, United Kingdom
Infect Immun 74:2706-16. 2006..Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge...
- Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccinationBruna C G de Alencar
Centro Interdisciplinar de Terapia Gênica CINTERGEN, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo, SP 04044 010, Brazil
Infect Immun 77:4383-95. 2009..Our study thus demonstrated a role for perforin and IFN-gamma in a number of T-cell-mediated effector functions and in the antiparasitic immunity generated by a heterologous plasmid DNA prime-adenovirus boost vaccination strategy...
- Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutantsDavid FitzSimons
World Health Organization, Via Appia 20, CH 1211 Geneva, Switzerland
Vaccine 23:4158-66. 2005..The main focus was on universal vaccination programmes with data being presented from Italy, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, The Gambia, and USA (Alaska)...
- Long-term protection of hepatitis B vaccine 18 years after vaccinationFaleh Alfaleh
Department of Medicine, College of Medicine, King Saud University, P O Box 2925 59, Riyadh 11461, Saudi Arabia
J Infect 57:404-9. 2008..This is the third evaluation study of the hepatitis B virus (HBV) vaccination program, initiated in 1989 in Saudi Arabia...
- Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus AnkaraJ Schneider
Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
Nat Med 4:397-402. 1998..DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells...
- Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineR R Amara
Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329, USA
Science 292:69-74. 2001..These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic...
- Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmidMasanori Matsui
Department of Microbiology, Saitama Medical School, Moroyama cho, Iruma gun, 350 0495, Saitama, Japan
Vaccine 21:1629-39. 2003..Thus, the prime-double boosts immunization together with IL-12 may be promising for HCV vaccine...
- IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infectionCarmel B Stober
Cambridge Institute for Medical Research, University of Cambridge, United Kingdom
J Immunol 175:2517-24. 2005..Anti-IL-10R treatment in vivo demonstrated that IL-10 was functional in determining vaccine failure, rendering LACK protective in the presence of high IFN-gamma/low IL-5 responses...
- Progress in DNA-based heterologous prime-boost immunization strategies for malariaAnne C Moore
Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
Immunol Rev 199:126-43. 2004..We summarize the preclinical design and development of these heterologous prime-boost vaccines and discuss the encouraging results that have been observed in vaccinated humans...
- Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccinationWolfgang Kastenmuller
Institute of Molecular Virology, Antigen specific Immunotherapy Clinical Cooperation Group, National Research Center for Environment and Health, 81675 Munich, Germany
J Exp Med 204:2187-98. 2007..Our findings provide a basis for novel strategies for how boost vaccination to defined antigens can be selectively improved. They give important new insights into the design of more efficient poxviral vectors for immunotherapy...
- Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian menE B Imoukhuede
MRC Laboratories, Banjul, Gambia
Vaccine 24:6526-33. 2006..This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines...
- Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsulesGeorge T Mercier
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, TX, USA
Vaccine 25:8687-701. 2007....
- Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adultsRicharda M de Voer
Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, 3720 BA Bilthoven, The Netherlands
Vaccine 27:6974-82. 2009..the kinetics of isotype-specific antibodies in adults (n=21) after primary immunization with MenCC or secondary immunization with MenCC or plain MenC polysaccharide vaccine...
- Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraDaniel P Webster
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
Proc Natl Acad Sci U S A 102:4836-41. 2005....
- Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosisMichael Santosuosso
Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Center for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
Infect Immun 74:4634-43. 2006..Our study demonstrates that intranasal administration of AdAg85A represents an effective way to boost immune protection by parenteral BCG vaccination...
- Secondary immunization generates clonally related antigen-specific plasma cells and memory B cellsDaniela Frölich
Department of Medicine, Rheumatology, and Clinical Immunology, Charite University Medicine Berlin, Germany
J Immunol 185:3103-10. 2010..The data indicate that although following secondary immunization PCs can derive from memory B cells without further somatic hypermutation, in some circumstances, likely ..
- Vaccine coverage levels after implementation of a middle school vaccination requirement, Florida, 1997-2000Kieran J Fogarty
Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention CDC, 1600 Clifton Rd, MS E 52, Atlanta, GA 30333, USA
Public Health Rep 119:163-9. 2004..This study examined coverage levels among students entering seventh grade in Florida following implementation of a school entry vaccination requirement in 1997...
- Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunityDan H Barouch
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
J Immunol 172:6290-7. 2004..Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity...
- Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsYuuei Shu
Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
Vaccine 25:1398-408. 2007....
- Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosisT Mark Doherty
Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark
Infect Immun 70:3111-21. 2002....
- Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunityJes Dietrich
Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, DK 2300 Copenhagen, Denmark
J Immunol 177:6353-60. 2006..tb in LTK63/Ag85B-ESAT-6-boosted mice, compared with BCG-vaccinated animals. Thus, LTK63/Ag85B-ESAT-6 represents an efficient preventive vaccine against tuberculosis with a strong ability to boost prior BCG immunity...
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNancy J Sullivan
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
Nature 424:681-4. 2003..This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses...
- A middle school immunization law rapidly and substantially increases immunization coverage among adolescentsFrancisco Averhoff
National Immunization Program, MS E 61, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
Am J Public Health 94:978-84. 2004..This study assessed the effectiveness of a middle school vaccination requirement for raising second-dose measles, mumps, and rubella vaccine and hepatitis B vaccine coverage among adolescents...
- Prime-boost immunisation strategies for tuberculosisHelen McShane
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
Microbes Infect 7:962-7. 2005..Using BCG as the priming immunisation in such a heterologous prime-boost strategy is a practical solution, which allows the beneficial effects of BCG in children to be maintained...
- Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coliM O Lasaro
Microbiology Department, Biomedical Science Institute, University of Sao Paulo, Av Prof Lineu Prestes 1374, Sao Paulo 05508 000, Brazil
Vaccine 23:2430-8. 2005....
- Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New GuineaB Genton
Papua New Guinea Institute of Medical Research, Goroka and Maprik, Papua New Guinea
Vaccine 18:2504-11. 2000..The vaccine induced good cellular responses, especially for MSP1 and RESA. Boosting of humoral responses was weak, probably because of high baseline antibody levels...
- Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitopeChristina M Ryan
Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA
J Immunol 177:255-67. 2006..These results indicate that epitope V provides a target for CD8+ T cells against spontaneous tumors in vivo, and suggests that epitopes with similar properties can be harnessed for tumor immunotherapy...
- A review of the long-term protection after hepatitis A and B vaccinationPierre Van Damme
Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerp, Belgium
Travel Med Infect Dis 5:79-84. 2007....
- Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populationsMartha Sedegah
Malaria Program, Naval Medical Research Center, Silver Spring, Maryland 20910 7500, USA
Infect Immun 70:3493-9. 2002..These results demonstrate that a heterologous priming and boosting vaccination can provide lasting protection against malaria in this model system...
- An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosisLaleh Majlessi
Biologie des Régulations Immunitaires, INSERM, E 352, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
Infect Immun 74:2128-37. 2006..These results question the broadly admitted correlation between the frequency of IFN-gamma-producing CD4+ T cells and the level of protection against tuberculosis...
- Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteinsGillis R Otten
Chiron Corporation, 4560 Horton St, Mail Stop 4 3, Emeryville, California 94608, USA
J Virol 79:8189-200. 2005....
- Polio extraimmunization in children younger than 2 years after changes in immunization recommendationsLoren K Mell
Center for Health Studies, Group Health Cooperative, Seattle, Washington, USA
Pediatrics 111:296-301. 2003..To investigate trends over time in polio extraimmunization among children in 4 large health maintenance organizations and to study the association with recent changes in polio immunization policy...
- Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian menVasee S Moorthy
Medical Research Council Laboratories, Banjul, Gambia
J Infect Dis 189:2213-9. 2004..These results highlight optimized combination regimens with general relevance to the development of vaccines targeting intracellular pathogens...
- Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNAH J Mollenkopf
Max Planck Institute for Infection Biology, Department of Immunology, Schumannstr 21 22, 10117 Berlin, Germany
Vaccine 19:4028-35. 2001..Vaccination with a single dose of r S. typhimurium secreting ESAT-6 reduced numbers of tubercle bacilli in the lungs throughout the course of infection. The combined prime-boost vaccination did not considerably enhance protection...
- Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescenceMarianne A B van der Sande
Medical Research Council Laboratories, Fajara, The Gambia
PLoS ONE 2:e753. 2007..These children are now in adolescence and approaching adulthood, when the onset of sexual activity may challenge their hepatitis B immunity. Thus a booster dose in adolescence could be important to maintain long-term protection...
- Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunizationWentao Gao
Department of Surgery and Medicine, University of Pittsburgh School of Medicine, Molecular Medicine Institute, Suite 412, 300 Technology Drive, Pittsburgh, PA 15219, USA
J Virol 80:1959-64. 2006....
- Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challengeN A Doria-Rose
Seattle Biomedical Research Institute, University of Washington, Seattle, Washington 98109, USA
J Virol 77:11563-77. 2003..03). We conclude that multigene vaccines delivered by a combination of vaccinia virus and gene gun-delivered DNA were effective against SHIV89.6P viral challenge in M. nemestrina...
- Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is lowElizabeth H Boxall
Health Protection Agency, West Midlands Public Health Laboratory, Heartlands Hospital, Birmingham, United Kingdom
J Infect Dis 190:1264-9. 2004..The long-term response to hepatitis B vaccination during infancy has not been fully evaluated in countries where endemicity is low...
- Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccineJohn J Treanor
Department of Medicine, University of Rochester, Rochester, NY, USA
N Engl J Med 354:1343-51. 2006..Influenza A (H5N1) viruses could cause a severe worldwide epidemic, with high attack rates, large numbers of deaths and hospitalizations, and wide disruption. Effective vaccines against these viruses in humans are urgently needed...
- Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh
Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences AFRIMS, Bangkok, Thailand
Vaccine 24:4167-78. 2006..In field studies, RTS,S/AS02A reduced malaria infection, clinical episodes, and disease severity. Heterologous prime-boost immunization regimens, optimally spaced, might improve the protective immunity of RTS,S/AS02A...
- The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosisClaire Swetman Andersen
Staten Serum Institute, TB Vaccine Research, Department of Infectious Disease Immunology, 5 Artillerivej, DK 2300 Copenhagen S, Denmark
Infect Immun 75:408-16. 2007..Thus, the results demonstrate the effectiveness of mucosal vaccination with Ag85B-ESAT-6 mixed with CTA1-DD/ISCOMs as adjuvant for stimulating TB-specific protective immunity in the lung...
- Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birthM J Saffar
Pediatric Infectious Diseases Ward, Department of Pediatrics Mazandaran Medical Sciences University, Boalisina Hospital, Pasdaran Boulevard, Sari Iran
Indian Pediatr 41:1232-7. 2004..Although nearly 42% of them were not seroprotected, but most of boosted subjects (87.3%) retained robust immunologic memory and rapidly retained a protective anti-HBs antibody titer of at least 10 IU/L after booster vaccination...
- Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosisH McShane
Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Infect Immun 69:681-6. 2001....
- The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protectionS Coulibaly
Baxter Vaccine AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
Virology 341:91-101. 2005..Similar to MVA, prime-boost immunizations with defective vaccinia induced robust long-term immunity, suggesting it as a promising next generation smallpox vaccine...
- The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challengeS Mendez
Laboratory of Parasitic Diseases and Laboratory of Clinical Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 166:5122-8. 2001..These data suggest that under conditions of natural challenge, DNA vaccination has the capacity to confer complete protection against cutaneous leishmaniasis and to prevent the establishment of infection reservoirs...
- A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccinesCristina Giambi
Communicable Disease Epidemiology Unit, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
BMC Infect Dis 8:100. 2008..The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine...
- Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workersAnnarosa Floreani
Department of Surgical and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, 35128 Padua, Italy
Vaccine 22:607-10. 2004..Overall, the anti-HBs seroprotection rate was 95.4% (102 subjects). Based on GMT results, no booster dose is necessary in healthy adults for at least 10 years after primary immunization...
- Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single doseJ Wiström
Department of Infectious Diseases, University Hospital of Umea, Sweden
Vaccine 17:2162-5. 1999..In conclusion, one single dose of HB vaccine seemed to confer on young healthy individuals a well preserved B cell memory, disclosed as a rapid and strong antibody response to a second dose four years later...
- Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity countryBernard Duval
Institut National de Sante Publique du Quebec, Quebec, Canada
Pediatr Infect Dis J 24:213-8. 2005..The long term effect of the booster dose in teenagers is unknown. We evaluated the immunogenicity of 2 pediatric hepatitis vaccines after primary vaccination and after a booster dose...
- Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virusRichard J Anderson
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
J Immunol 172:3094-100. 2004..berghei and was more immunogenic and protective than DNA/MVA prime/boost immunization. However, further improvement was not achieved by sequential (triple) immunization with a DNA vaccine, FP9, and MVA...
- Recent developments in tuberculosis vaccinesMelles Haile
Department of Bacteriology, Swedish Institute for Infectious Disease Control, Solna, Sweden
Curr Opin Infect Dis 18:211-5. 2005..Some new TB vaccines, which have entered or are expected to enter clinical trials, are highlighted...
- A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of lifeSalvacion Gatchalian
Research Institute for Tropical Medicine, Filinvest Corporate Centre, Alabang, Muntinlupa City, Manila, Philippines
Hum Vaccin 4:60-6. 2008..Combined DTPw-HBV and DTPw-HBV/Hib vaccines using new vaccine antigen sources will promote continued supply of combined DTPw-based vaccines to global mass vaccination campaigns...
- Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 yearsLaura L Hammitt
Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, AK, USA
Vaccine 25:6958-64. 2007..These children had protective anti-HBs concentrations when tested after receiving a three-dose series of 2.5 microg recombinant hepatitis B vaccine starting at birth...
- Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccineB Watson
Albert Einstein Medical Center and The Philadelphia Department of Health, Division of Disease Control, Immunization Program, 500 S Broad Street, Philadelphia, PA 19146, USA
Vaccine 19:3164-8. 2001..Significantly even the 5 individuals with less than 10 mIU/ml of anti-HBs prior to the booster all had impressive responses to the booster dose...
- A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin AmericaMiguel Tregnaghi
Centro de Desarrollo de Proyectos Avanzados, Cordoba, Argentina
Rev Panam Salud Publica 19:179-88. 2006....
- Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c MiceCarmel B Stober
Cambridge Institute for Medical Research, Wellcome Trust MRC Building, Addenbrooke s Hospital, Hills Rd, Cambridge, CB2 2XY, United Kingdom
Infect Immun 75:852-60. 2007..major challenge Th1 response compared to the Th2/T(reg) response. Thus, TRYP DNA/TRYP MVA, but not TRYP DNA alone, provides long-term protection against murine leishmaniasis...
- Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birthDexter Seto
Kapiolani Medical Center for Women and Children, Honolulu, HI 96826, USA
Pediatr Infect Dis J 21:793-5. 2002..Although nearly one-half had become seronegative, all retained robust immunologic memory and rapidly regained a protective anti-HBs titer of at least 10 mIU/ml after booster vaccination...
- Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistenceU Heininger
University Children s Hospital, Division for Pediatric Infectious Diseases and Vaccinology, Basel, Switzerland
Vaccine 25:1055-63. 2007....
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaK G Nicholson
Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
Lancet 357:1937-43. 2001..We did an observer-blind, phase I, randomised trial in healthy volunteers to assess safety, tolerability, and antigenicity of MF59-adjuvanted and non-adjuvanted vaccines...
- Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boostLasse Vinner
Department of Virology, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark
J Gen Virol 84:203-13. 2003..The demonstrated humoral and cellular immunogenicities of these HIV Bx08 Env vaccines in non-human primates encourages their further development as one component in candidate HIV vaccines for humans...
- DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American childrenJose Ignacio Santos
Departamento de Medicina Experimental, Facultad de Medicina UNAM and Conrejo Nacional de Vacunación, Ministry of Health, Mexico
Vaccine 20:1887-93. 2002..These results suggest that the combination of DTPw-HB and Hib vaccines provides an effective means for increasing vaccine coverage in childhood vaccination programmes...
- Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectorsDanilo R Casimiro
Department of Viral Vaccine Research, Merck Research Laboratories, Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, USA
J Virol 78:11434-8. 2004..The heterologous Ad5 priming-poxvirus boosting approach may have potential utility in humans as a means of inducing high levels of cellular immunity...
- Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancyTaraz Samandari
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Pediatrics 120:e373-81. 2007..The duration of protection provided by hepatitis B vaccination is unknown, but the presence of immune memory can be evaluated indirectly by measuring the immune response to a booster dose of vaccine...
- Competition between CTL narrows the immune response induced by prime-boost vaccination protocolsMichael J Palmowski
Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
J Immunol 168:4391-8. 2002..Our findings define a novel vaccination strategy optimized for the induction of an effective polyvalent cytotoxic response...
- Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trialMecky Matee
Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
J Infect Dis 195:118-23. 2007..Most new tuberculosis vaccines will be administered as a booster to subjects primed with bacille Calmette-Guérin (BCG) during childhood...
- Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineRama Rao Amara
Vaccine Research Center, Yerkes Regional Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329, USA
Vaccine 20:1949-55. 2002..These highly promising findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic...
- Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte populationMarie J Estcourt
John Curtin School of Medical Research, Australian National University, Canberra, ACT 2610, Australia
Int Immunol 14:31-7. 2002..Strategies that generate specific T cells of high avidity, optimizing early detection of infected cells, offer new hope for effective prophylaxis and immunotherapy...
- Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysisD J Balestra
Department of Medicine, Veterans Affairs Medical and Regional Office Center, White River Junction, VT 05009
J Gen Intern Med 8:405-12. 1993....
- Prime-boost immunization strategies for infectious diseasesHelen McShane
Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, UK
Curr Opin Mol Ther 4:23-7. 2002..Prime-boost immunization strategies involve using two different vaccines, each encoding the same antigen, some weeks apart. Such strategies have been shown to enhance cellular immunity in several different animal and disease models...
- [Why are boosters no longer necessary for protection against hepatitis B?]Claire Anne Siegrist
Centre de vaccinologie et d immunologie néonatale, Universite de Geneve, C M U, 1211 Geneve 4, Suisse
Rev Prat 54:509-11. 2004..This resulted into a change of initial recommendations, which now highlight that booster doses are unnecessary in immunocompetent persons after a complete course of vaccination...
- Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaquesW O Rogers
Malaria Program, Naval Medical Research Center, Silver Spring, Maryland 20910, Bethesda, Maryland 20889, USA
Infect Immun 69:5565-72. 2001..This model will be important in preclinical vaccine development...
- Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccinationIan T Williams
Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30030, USA
Pediatr Infect Dis J 22:157-63. 2003..Few studies have examined the long term persistence of antibody after hepatitis B immunization beginning at birth and the response to a subsequent challenge with a booster dose of vaccine...
- Hepatitis B vaccine -- do we need boosters?J E Banatvala
Clinical Virology, Guys Kings and St Thomas School of Medicine and Dentistry, Clinical Virology, London, UK
J Viral Hepat 10:1-6. 2003..If implemented, this recommendation will have considerable cost benefits world-wide...
- Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACKMaria J Ramiro
Centro de Investigaciones Biologicas, Velazquez 144, CSIC, Madrid 28006, Spain
Vaccine 21:2474-84. 2003..This type of DNA/rVV prime/boost immunization approach may have utility against visceral leishmaniasis in dogs...
- Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimenWilliam O Rogers
Malaria Program, Naval Medical Research Center, Silver Spring, Maryland 20910, USA
Infect Immun 70:4329-35. 2002..These findings demonstrate that a multistage, multiantigen, DNA priming and poxvirus boosting vaccine regimen can protect nonhuman primates from an otherwise lethal malaria sporozoite challenge...
- SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirusPatrick C Y Woo
Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong
Vaccine 23:4959-68. 2005..The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems...
- Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunityClaire L Hutchings
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
J Immunol 175:599-606. 2005....
- DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody responseArchana Rath
Gamete Antigen Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India
Virus Res 113:143-52. 2005..The present results demonstrate that a DNA vaccine encoding the full-length sequence of the ectodomain plus TD of the mature native RV-G is capable of expressing an 'ideal' immunogen to produce RVNA titers...
- A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasisPoonam Tewary
School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
J Infect Dis 191:2130-7. 2005..We describe the effectiveness of a prime-boost vaccination regimen using the open-reading frame (ORFF) gene from the LD1 locus of Leishmania donovani...
- Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesSampa Santra
Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P O Box 15732, Boston, MA 02215, USA
J Virol 79:6516-22. 2005..Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection...
- Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gammaFernando Abaitua
Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Campus Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
Virus Res 116:11-20. 2006..The increment of the CD8+ T cell response was higher in a DNA/MVA prime/boost protocol. Thus, the immune response of MVA vectors can be improved with the co-delivery of the cytokines IFN-gamma or IL-12...
- Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18Ma Mingxiao
Genetic Engineering Laboratory, Academy of Military Medical Sciences, Changchun 130062, PR China
Antiviral Res 76:59-67. 2007..The results demonstrate the potential viability of a DNA vaccine in the control and prevention of FMDV infections...
- Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccinationRui Ma
Department of Immunology, Zhongshan School of Medicne, Sun Yat Sen University, Guangzhou, People s Republic of China
Biochem Biophys Res Commun 361:537-42. 2007..Taken together, our results imply that CpG ODN and R-848 may be the candidates as adjuvants for use in prophylactic and therapeutic hepatitis B vaccine...
- Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120Farley Cleghorn
Center for HIV AIDS, Constella Futures, Washington, DC, USA
J Acquir Immune Defic Syndr 46:222-30. 2007..vCP1452 was administered alone or with a heterologous boost of MN rgp120 glycoprotein. The trial was pivotal in deciding whether these vaccines advanced to phase 3 efficacy trials...
- DNA priming and killed virus boosting vaccination strategy can augment the immune response to pseudorabies virusZ H Chen
College of Veterinary Medicine, China Agricultural University, Beijing, China
Acta Virol 51:163-70. 2007..The results suggested that DNA priming followed by KV vaccine boosting could enhance the antibody response and cellular immunity against PRV infection in mice...
- Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype CWendy A Burgers
Institute of Infectious Disease and Molecular Medicine and Division of Medical Virology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa
AIDS Res Hum Retroviruses 24:195-206. 2008..An accompanying paper describes the immunogenicity of SAAVI MVA-C when given in combination with SAAVI DNA-C...
- A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in miceEnid Shephard
Institute of Infectious Disease and Molecular Medicine and Division of Medical Virology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa
AIDS Res Hum Retroviruses 24:207-17. 2008..The demonstration that these vaccines induce potent cellular immune responses merits their testing in clinical trials...
- Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunityJin Su
BioTherapeutics Research Group, Robarts Research Institute, Canada Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada, N6A 5K8
Virology 375:48-58. 2008..This vaccine strategy may facilitate the generation of an efficacious vaccine for HIV, and other chronic diseases that require enhanced cell-mediated immunity, including HCV and metastatic cancer...
- Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection modelSilvia I Cazorla
Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral IDEHU, CONICET UBA, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Junin 956 4to P, 1113 Buenos Aires, Argentina
Vaccine 26:1999-2009. 2008..This prime-boost regimen appears promising for further development, since warranted survival, provided efficient control of parasite load and restricted inflammatory myopathy...
- Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenzaVictor C Huber
Deparment of Infectious Disease, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
Clin Vaccine Immunol 13:981-90. 2006..This study details separate but important roles for both IgG1 and IgG2a expression in vaccination against influenza and argues for the development of vaccine regimens that stimulate and measure expression of both antibody isotypes...
- Protective immune responses induced by different recombinant vaccine regimes to Rift Valley feverD B Wallace
Onderstepoort Veterinary Institute, Onderstepoort, South Africa
Vaccine 24:7181-9. 2006..Vaccinated sheep sero-converted for both viruses and were protected against RVFV challenge, however, neither the immunised or negative control animals showed any significant reactions to the virulent SPV challenge...
- Group 1 CD1 in Infectious Disease and T Cell DevelopmentChyung Ru Wang; Fiscal Year: 2013..Mtb lipids elicit group 1 CD1-restricted Mtb- lipid antigen-specific T cell responses in hCD1Tg mice, and secondary immunization induces more rapid responses than primary immunization...
- Regulation of murine neonatal Th2 functionREBECCA D ADKINS; Fiscal Year: 2010..This idea is supported by our findings that the function of peripheral CD4+ cells in neonates resembles that of RTE in adults. ..
- Complement as an Adjuvant in Polysaccharide ImmunitySAMUEL TEST; Fiscal Year: 2003..pneumoniae will be prepared and evaluated in different strains of mice. These experiments should provide new insights into the immune response to conjugate vaccines and facilitate future efforts to improve vaccine efficacy. ..
- AGING AND IMMUNITY IN TUBERCULOSISIan Orme; Fiscal Year: 2002....
- Chronic Tuberculosis: Latent or DynamicIan Orme; Fiscal Year: 2008..unreadable] [unreadable]..
- Role of DAP12 in type 1 anti-mycobacterial immunityZhou Xing; Fiscal Year: 2005..We strongly believe that our studies will provide new insights into the mechanisms of type 1 anti-microbial immunity and novel targets for immune modulation. ..
- Polyvalent DNA Plus Protein HIV VaccinesShan Lu; Fiscal Year: 2010..This will allows us to effectively screen a large number of unique primary Env antigens to formulate the effective polyvalent HIV vaccines for the next phase of clinical testing. ..
- STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCREIan Orme; Fiscal Year: 2004..abstract_text> ..
- Vaccine Induced Mucosal Protection Against TB InfectionDANIEL HOFT; Fiscal Year: 2005..Prime/boosting strategies found to prevent BCG infection after aerosol challenges will be studied for the ability to prevent infection with virulent M. tuberculosis by aerosol challenge. ..
- Multi-gene plague vaccine with expanded protectionShan Lu; Fiscal Year: 2004..This project will employ the most advanced DNA immunization technology in combination with small-scale protein production to quickly develop potential subunit-based plague vaccine products. ..
- Guinea pig model for TB vaccine evaluationsIan Orme; Fiscal Year: 2007..unreadable] [unreadable]..
- DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSISIan Orme; Fiscal Year: 2006..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
- Immune Responses to Biodefense Vaccines Early in LifeMarcela F Pasetti; Fiscal Year: 2010..It will also provide knowledge to better understand the mechanisms mediating neonatal-infant immunity to develop more effectivevaccines to prevent diseases early in life. ..
- TRYPANOSOMA CRUZI MUCOSAL & SYSTEMIC PROTECTIVE IMMUNITYDANIEL HOFT; Fiscal Year: 2008..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. [unreadable] [unreadable]..
- Characterization of the M. tuberculosis phagosomeMARCUS HORWITZ; Fiscal Year: 2007..These experiments will advance our understanding of the cell biology and pathogenic mechanisms of M. tuberculosis and facilitate the development of new strategies to combat tuberculosis. [unreadable] [unreadable]..
- Novel Antimicrobial Agents Against M. tuberculosisMARCUS HORWITZ; Fiscal Year: 2008..mammalian GS, and test the toxicity of the analogs in mice. 2) Test the novel MSO analogs for their capacity to inhibit M. tuberculosis growth in broth culture, in human macrophages, and in guinea pigs. ..
- Neonatal Immunization with Acellular Pertussis VaccinesNatasha Halasa; Fiscal Year: 2007....
- CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITYDaniel Smith; Fiscal Year: 2007..unreadable]..
- Immunotherapy for Pancreatic Amylin Aggregates in DiabetesEinar Sigurdsson; Fiscal Year: 2008..These studies could lead to novel treatments for type-2 diabetes. [unreadable] [unreadable] [unreadable]..
- Genomics of Susceptibility to Urinary Tract InfectionsWALTER HOPKINS; Fiscal Year: 2007..coli strains or non-E, coil bacteria. These objectives will be accomplished using a well-established mouse model of ascending UTI, genetic linkage analysis, and evaluation of resistance to uropathogens in congenic mice. ..
- Dynamics of TCR Repertoire Following Thymus TransplantMARY MARKERT; Fiscal Year: 2008..These findings will have application to thymus and bone marrow transplantation for immunodeficiency and cancer. ..
- Immunobiological Role of Fertilization Antigen(FA-1)RAJESH NAZ; Fiscal Year: 2007..unreadable] [unreadable]..
- Reconstitution of Protective CMV Immunity and Immune Regulation After HAARTAdriana Weinberg; Fiscal Year: 2008..These analyses will define the role of TREG in the inadequate CMV immune reconstitution of HAART recipients. [unreadable] [unreadable] [unreadable] [unreadable]..
- T-Cell Responses Predict Influenza Risk in Older AdultsJanet E McElhaney; Fiscal Year: 2010..3) Test heat shock proteins (Hsp) as potential vaccine adjuvants to enhance the CTL response to vaccination. ..
- Memory T cell subsets and pulmonary immunityDavid L Woodland; Fiscal Year: 2010....
- Poly-functional analyses of vaccine-induced T cell responsesGuido Ferrari; Fiscal Year: 2010..Overall, these findings will shed new insights on the importance and fate of vaccine-induced T cell responses in controlling HIV-infection. ..
- Studies on the Eppin family of proteins on chromosome 20MICHAEL G O apos RAND; Fiscal Year: 2010..This aim will test the hypothesis that anti-Eppin antibodies disrupt Eppin's modulation of PSA activity. ..
- HIV Testing and Women's Attitudes on HIV Vaccine TrialsGregory D Zimet; Fiscal Year: 2010..abstract_text> ..
- A TB Vaccine for AIDS PatientsMARCUS AARON HORWITZ; Fiscal Year: 2010..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
- Tuberculosis Diagnostics: Towards More Precise Testing in ChildrenJoseph Bellanti; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Dose Study of thymus TransplantationMARY MARKERT; Fiscal Year: 2007..Abstract Not Provided. ..
- Role of E. coli Virulence Factors in Chronic Prostate Infection and InflammationWALTER HOPKINS; Fiscal Year: 2008..coli genes play a direct or indirect role in development of prostatic lesions. Results of these studies can lead to new methods to prevent or treat chronic bacterial prostatitis. [unreadable] [unreadable] [unreadable]..
- Respiratory Immunity Against Agents of BioterrorismSTEVEN MIZEL; Fiscal Year: 2008....
- Regulation of CD8+ T cell responses to influenza virusDAVID WOODLAND; Fiscal Year: 2007..abstract_text> ..
- Papillomavirus E2 as a cervical/anal cancer drug targetJanet Brandsma; Fiscal Year: 2005..Vectors containing a conditional wild-type CRPV E2 transgene will be used to determine the effects of E2 overexpression. ..
- Parathyroid and Thymus Transplants in DiGeorge SyndromeMARY MARKERT; Fiscal Year: 2005..Indirect allorecognition as a mechanism of graft rejection will be assessed by ELISpot. The third aim will assess safety and tolerability. ..
- Acellular vaccines against Francisella tularensisWayne Conlan; Fiscal Year: 2005..It is expected that the findings from the proposed studies will be applicable to the development of acellular vaccines against other intracellular respiratory pathogens such as Mycobacterium tuberculosis, and Chlamydia pneumoniae. ..
- Chimeric Adenovirus Vaccine Vectors for HIV/SIVDAN BAROUCH; Fiscal Year: 2005..Within the two-year time frame of this award, sufficient data will be generated with candidate chimeric rAd vaccines to justify further vaccine/challenge studies in rhesus monkeys. ..
- URINARY TRACT INFECTIONS--IMMUNE BASIS OF SUSCEPTIBILITYWALTER HOPKINS; Fiscal Year: 2003....
- IMMUNIZATION AGAINST TUMOR CELL ANTIGENSPaul Chapman; Fiscal Year: 2003..This close mentoring relationship reflects our current teaching paradigm. The grant award will provide the PI with more time to conduct the clinical trials and to mentor additional beginning clinical investigators. ..
- NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITISEUGENE ST CLAIR; Fiscal Year: 2003..St.Clair with outstanding clinical research opportunities and educational experiences for his trainees. ..
- M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITIONMARCUS HORWITZ; Fiscal Year: 2002..tuberculosis glutamine synthetase, they hope to develop more active entities than the parent compound and thereby to develop a new antibiotic against M. tuberculosis. ..
- COUNTER REGULATION OF STRESS MEDIATED IMMUNOSUPPRESSIONDavid Padgett; Fiscal Year: 2002..The long-term goals should provide insight into the relationships between the nervous, endocrine, and immune systems and how inflammatory immune responses can be regulated at many different central and peripheral levels. ..
- SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESISAlan Cross; Fiscal Year: 2002..These studies will define a new mechanism for a rapidly adaptable, temporally- restricted local response to inflammation. This proposal will provide new targets and additional approaches to the treatment of inflammation. ..
- INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSISAlan Cross; Fiscal Year: 2001..The demonstration of a spectrum of responses to LPS in these studies may identify the earliest changes in cytokine responses that predict the development of sepsis. ..
- IMMUNIZATION AGAINST URINARY TRACT INFECTIONDAVID UEHLING; Fiscal Year: 2001..2. Utilize an animal model to clarify the immunologic basis for the increased resistance to UTI following vaginal immunization and to evaluate adjuvants and vaccination regimes that optimize immunogenicity and efficacy of UTI vaccines. ..
- IMMUNE CONTROL OF CAE LENTIVIRUSDonald Knowles; Fiscal Year: 2005..Therefore, the second objective of this proposal is to evaluate virus replication following CAEV challenge of goats co-immunized with plasmid DNA expressing CAEV env and tat genes and caprine IFN. ..
- Familial IgA Nephropathy: Genetic and Metabolic StudiesJiri Mestecky; Fiscal Year: 2006..abstract_text> ..
- Whole Autologous SIV Vaccine Using Dendritic CellsSIMON BARRATT BOYES; Fiscal Year: 2006....
- Bacterial Vaccine Antigen DiscoveryLAWRENCE PAOLETTI; Fiscal Year: 2006..Aim 2). Findings from these studies utilizing this unique approach to vaccine antigen discovery could be directly applied to other bacterial pathogens. ..
- Novel broad spectrum vaccination against influenzaPetr Ilyinskii; Fiscal Year: 2006..The overall aim of this project is to demonstrate better protective effect or/and enhanced immune response using modified influenza proteins as immunogens compared to wild-type viral proteins. ..
- Phase II trial of 17-AAG in melanoma patientsPaul Chapman; Fiscal Year: 2007..post-treatment specimens, clinically responding tumors vs. non-responding tumors, and mutant BRAF vs. wild-type BRAF tumors. [unreadable] [unreadable] [unreadable]..
- Protective Immune Responses in HIV-1 Exposed InfantsCarey Farquhar; Fiscal Year: 2006..Kreiss and John, will prepare her for the complex data analysis required by this study and contribute substantially to the development of her career as an independent clinical investigator. ..
- Interventions to Increase HBV Vaccination in STD ClinicsGregory Zimet; Fiscal Year: 2006..The relationships of the interventions, socio-demographics, attitudes and behaviors to the outcome measures will be assessed with multiple logistic regression (MLR) and path analysis via structural equation modeling. ..
- PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATIONJiri Mestecky; Fiscal Year: 2006..Results of these studies will generate information concerning previously unexplored inflammatory pathways that participate in the development of PD. ..
- VZV Receptors and Infective MechanismsAnne Gershon; Fiscal Year: 2007..It may also make it possible to develop a safer and more efficacious vaccine. ..
- Protective cellular immune responses in HIV-1 discordant couplesCarey Farquhar; Fiscal Year: 2010....
- PEDIATRICS AIDS CLINICAL TRIALS GROUPAnne Gershon; Fiscal Year: 2006..We have competent, outstanding staff whose aim is not only to provide compassionate medical care to HIV-infected patients but also to perform meaningful and useful research on prevention and treatment of HIV infection. ..
- Biodefense vaccine for pandemic influenzaLawrence Smith; Fiscal Year: 2005..FINAL MILESTONE 3: Completion of Aim 2 and completion of IND ..
- Design and Use of HIV V3 Mimetic ImmunogensSusan Zolla Pazner; Fiscal Year: 2008..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
- Activation of inflammatory cells by flagellinSTEVEN MIZEL; Fiscal Year: 2006..Furthermore, the proposed studies should also provide insights into the factors that regulate TLR signaling and allow for complex patterns of host cell response. ..
- Effects of Probiotic Lactobacilli on Rotavirus ImmunityLijuan Yuan; Fiscal Year: 2006..The findings from this study will also facilitate an understanding of the potential adjuvant effects of probiotics for development of more effective vaccines against rotavirus and other enteric virus-induced diseases. ..